Clinical Trial Search

Primary: Correlation Co-efficient Between MRS Spectroscopy and Endomyocardial Biopsy in Heart Transplant Participants — 0.97 correlation co-efficient — p=<0.05

Primary: MYCL — 0.54; 0.44; 0.35; 0.36 percentage of water signal

Primary: Myocaridal Lipid on MRS — 1.72; 1.18; 1.53; 0.93 ratios

Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Myocardial Fatty Acid Uptake Rate — 18.492; 2.123; 36.005; 7.8 umol/min/100g

Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min

Primary: Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) — 9; -10; 4; 2 mg/dL

Primary: The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With…

Primary: Coronary Flow Reserve — 2.65 ratio

Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio

Primary: Number of Participants Stratified as Non-Index Culprit Lesion Related Major Adverse Cardiac Events (NC-MACE) or No NC-MACE and Association With maxLCBI4mm as a…

Primary: Endothelial Glycocalyx Thickness — 2.28 micrometer

Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL

Primary: Peak Oxygen Uptake (VO2) — 26.1; 27.6 ml O2 uptake/kg fat-free mass/minute — p=0.26

Primary: Myocardial Fat Content — 1.7; 1.1 percentage of myocardium content

Primary: Percent Change in Insulin Sensitivity Compared to Baseline Measurement. — 31.8; 17.4; -4.8 Percent change

Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml

Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94

Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05

Primary: Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS) — 0.2; 1.2; 6.4; 0.8 percentage of total liver content…

Primary: Energy Expenditure — -73; 107 kcal/day

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05

Primary: Change in Endothelial Progenitor Cells — -10.01; 5.19 Percentage of EPCs

Primary: Cholesterol — 204; 201 mg/dl

Primary: Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30 — 110; 84.0 mg/dL

Primary: Postprandial Changes in Plasma Triglyceride Concentrations — 51; 90; 98 mmol/L x 360 min

Primary: Arachidonic Acid Level After 2 Weeks of Treatment — 259.1; 269.6 nmol — p=0.455

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants